Recombinant Human VCAM1(Phe25-Glu698) fused with His tag at the C-terminus was expressed in NS0.
Predicted N Terminal:
Lyophilized from a 0.2 μm filtered solution in PBS.
Measured by the ability of the immobilized protein to support the adhesion of U937 human histiocytic lymphoma cells. When 5 x 10^4 cells/well are added to human VCAM-1 coated plates (10 µg/mL with 100 µL/well), approximately 90-100% will adhere after 1 hour incubation at RT.Optimal dilutions should be determined by each laboratory for each application.
Predicted Molecular Mass: 101.6 (monomer) kDa;SDS-PAGE: 130-140 kDa, reducing conditions
<0.10 EU per 1 μg of the protein by the LAL method.
>95%, by SDS-PAGE under reducing conditions and visualized by silver stain
Avoid repeated freeze-thaw cycles.12 months from date of receipt, -20 to -70 centigrade as supplied.1 month, 2 to 8 centigrade under sterile conditions after reconstitution.3 months, -20 to -70 centigrade under sterile conditions after reconstitution.
Reconstitute at 100 μg/mL in sterile PBS.